Examkin

Question

Difficulty: Very hardNeurocognitive Disorders

A 78-year-old man with an 8-year history of Parkinson disease is brought to the geriatrics clinic by his daughter. Over the past 6 months, he has exhibited progressive memory loss, difficulty paying bills, and fluctuating attention. During the last 2 weeks, he has developed vivid, terrifying visual hallucinations of strangers in his bedroom, leading to severe agitation. His vital signs and physical examination are unchanged from his baseline. His current medications include carbidopa-levodopa, pramipexole, trihexyphenidyl, and omeprazole. The physician determines that a stepwise approach is required to manage his neuropsychiatric symptoms while attempting to preserve motor function.

Arrange the following management steps in the most appropriate sequential order, from the initial most necessary action to the final therapy of last resort.

  1. 1Perform laboratory testing (e.g., urinalysis, comprehensive metabolic panel) to evaluate for underlying reversible systemic causes.
  2. 2Discontinue trihexyphenidyl.
  3. 3Taper and discontinue pramipexole.
  4. 4Initiate therapy with rivastigmine.
  5. 5Initiate therapy with low-dose quetiapine or pimavanserin.

Answer

The correct sequence is: 1) Evaluate for systemic causes of delirium, 2) Discontinue anticholinergics (trihexyphenidyl), 3) Taper dopamine agonists (pramipexole), 4) Initiate an acetylcholinesterase inhibitor (rivastigmine), and 5) Initiate a targeted atypical antipsychotic (quetiapine/pimavanserin).
The algorithmic management of psychosis in Parkinson disease requires a stepwise approach that balances psychiatric symptom control with motor function preservation. Any subacute change in behavior must first prompt an evaluation for delirium (e.g., infections, metabolic disturbances). Once ruled out, the physician should incrementally simplify the medication regimen. Medications with the highest risk of neuropsychiatric side effects and lowest motor benefit are discontinued first: anticholinergics (trihexyphenidyl) > amantadine > MAO-B inhibitors > dopamine agonists (pramipexole) > COMT inhibitors. Carbidopa-levodopa is reduced last, only if absolutely necessary. If psychosis persists despite optimizing the regimen, an acetylcholinesterase inhibitor (rivastigmine) is often added, particularly if cognitive impairment (Parkinson disease dementia) is present. If symptoms remain severe and distressing, an atypical antipsychotic with low D2 affinity (quetiapine, clozapine) or a 5-HT2A inverse agonist (pimavanserin) is initiated as a last resort.

Step-by-Step Solution

1
Evaluate for systemic causes of delirium.
Identifies or excludes acute medical illnesses such as urinary tract infections or metabolic derangements.
Patients with underlying major neurocognitive disorders are highly susceptible to delirium. An acute change in mental status (over 2 weeks) mandates ruling out reversible medical causes before adjusting psychiatric or neurologic medications.
2
Simplify the antiparkinsonian regimen by discontinuing anticholinergics (trihexyphenidyl).
Removes the medication with the highest risk of causing confusion and hallucinations.
Anticholinergics impair cognition and frequently cause visual hallucinations in the elderly. They offer minimal motor benefit compared to levodopa and are the first agents to be stopped.
3
Taper and discontinue dopamine agonists (pramipexole).
Reduces dopaminergic overstimulation in the mesolimbic pathway.
If symptoms persist, other adjunctive medications (amantadine, MAO-B inhibitors, then dopamine agonists) are sequentially reduced. Dopamine agonists are notorious for causing psychosis and impulse control disorders.
4
Initiate an acetylcholinesterase inhibitor (rivastigmine).
Enhances central cholinergic transmission.
In patients with Parkinson disease dementia experiencing psychosis, cholinesterase inhibitors can improve both cognitive function and behavioral symptoms without significantly worsening motor function.
5
Initiate a low-affinity D2 receptor antagonist (quetiapine) or a 5-HT2A inverse agonist (pimavanserin).
Directly targets psychotic symptoms as a therapy of last resort.
If psychosis remains severe and distressing despite the above measures, targeted antipsychotics are used. Typical antipsychotics and most atypicals (e.g., risperidone) are contraindicated due to severe worsening of parkinsonism.

Key Concept

Algorithmic management of psychosis and agitation in Parkinson Disease Dementia.
Rate this question

Topics

Neurocognitive Disorders

More questions from this topic